NCT02740972View on ClinicalTrials.gov

Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

April 30, 2018

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

NS-065/NCNP-01

DRUG

Placebo

Trial Locations (7)

95817

UC Davis, Sacramento

Unknown

University of Florida Health, Gainesville

Lurie Children's Hospital, Chicago

Washington University, St Louis

Duke University Medical Center, Durham

Children's Hospital of Richmond at VCU, Richmond

Alberta Children's Hospital, Calgary

Sponsors

Lead Sponsor

NS Pharma, Inc.

Collaborators (1)

Nippon Shinyaku Co., Ltd.
All Listed Sponsors
collaborator

Nippon Shinyaku Co., Ltd.

INDUSTRY

collaborator

Cooperative International Neuromuscular Research Group

NETWORK

collaborator

Therapeutic Research in Neuromuscular Disorders Solutions

INDUSTRY

lead

NS Pharma, Inc.

INDUSTRY

NCT02740972 - Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter